Back to Authors

Hunt, Jennifer L.

Mayo Clinic

University of Arkansas at Little Rock

Citations 2

Surgical Pathology Report Defects: A College of American Pathologists Q-Probes Study of 73 Institutions
Volmar, Keith E., Hunt, Jennifer L., Souers, Rhona J., Meier, Frederick A., Nakhleh, Raouf E. , Idowu, Michael O.

Archives of Pathology and Laboratory Medicine | April 30, 2014 | Volume: 138 | Issue: 5 | Pages: 602-612

10.5858/arpa.2013-0099-cp Get It

Context .—The rate of surgical pathology report defects is an indicator of quality and it affects clinician satisfaction. Objective .—To establish benchmarks for defect rates and defect fractions through a large, multi-institutional prospective application of standard taxonomy. Design .—Participants in a 2011 Q-Probes study of the College of American Pathologists prospectively reviewed all surgical pathology reports that underwent changes to correct defects and reported details regarding the defects. Results .—Seventy-three institutions reported 1688 report defects discovered in 360 218 accessioned cases, for an aggregate defect rate of 4.7 per 1000 cases. Median institutional defect rate was 5.7 per 1000 (10th to 90th percentile range, 13.5–0.9). Defect rates were higher in institutions with a pathology training program (8.5 versus 5.0 per 1000, P = .01) and when a set percentage of cases were reviewed after sign-out (median, 6.7 versus 3.8 per 1000, P = .10). Defect types were as follows: 14.6% misinterpretations, 13.3% misidentifications, 13.7% specimen defects, and 58.4% other report defects. Overall, defects were most often detected by pathologists (47.4%), followed by clinicians (22.0%). Misinterpretations and specimen defects were most often detected by pathologists (73.5% and 82.7% respectively, P < .001), while misidentifications were most often discovered by clinicians (44.6%, P < .001). Misidentification rates were lower when all malignancies were reviewed by a second pathologist before sign-out (0.0 versus 0.6 per 1000, P < .001), and specimen defect rates were lower when intradepartmental review of difficult cases was conducted after sign-out (0.0 versus 0.4 per 1000, P = .02). Conclusion .—This study provides benchmarking data on report defects and defect fractions using standardized taxonomy.
Desmoid tumors of the head and neck: A therapeutic challenge
Bree, Eelco de , Zoras, Odysseas , Hunt, Jennifer L., Takes, Robert P. , Hinni, Michael L., Rodrigo, Juan P. , Shaha, Ashok R. , Rinaldo, Alessandra , Ferlito, Alfio , Suarez, Carlos M. , Mendenhall, William M , Bree, Remco de , Rodrigo, Juan P

Head & Neck | October 12, 2013 | Volume: 36 | Issue: 10 | Pages: 1517-1526

10.1002/hed.23496 Get It

AbstractDesmoid tumor, or aggressive fibromatosis, is a rare, histologically benign, fibroblastic lesion that infrequently presents in the head and neck. Desmoid tumors often grow locally, invasively, and may, in rare instances, be fatal secondary to invasion into critical structures, such as airway or major vessels. The most common treatment is surgery, but desmoid tumors are characteristically associated with a high local recurrence rate after resection. Although the margin status seems to be of importance, operations that avoid function loss and esthetic disfigurement should be the primary goal. The efficacy of postoperative radiotherapy is controversial. Its potential benefit should be carefully balanced against possible radiation‐induced adverse effects. Alternative treatment modalities, such as primary radiotherapy and medical treatment or a wait‐and‐see policy, may be preferable to mutilating surgery. Considering all the aforementioned, it seems obvious that desmoid tumors of the head and neck present a therapeutic challenge and require an individualized approach. © 2014 Wiley Periodicals, Inc.Head Neck, 36: 1517–1526, 2014